Advanced search
Publication Cover
OncoTargets and Therapy Volume 11, 2018 - Issue
Submit an article Journal homepage
169
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients

Zhefeng Liu1 Department of Oncology, Chinese PLA General Hospital, Beijing, People’s Republic of China, [email protected]
,
Lin Wu2 Department of the Second Chest Medicine, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China
,
Jun Cao3 Department of Oncology, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China
,
Zhe Yang4 Department of Radiotherapy, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, People’s Republic of China
,
Chengzhi Zhou5 State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China
,
Liming Cao6 Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China
,
Hao Wu7 Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, People’s Republic of China
,
Haibo Shen8 Department of Thoracic Surgery, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China
,
Meiling Jin9 Department of Respiratory Medicine, Zhongshan Hospital Affiliated with Fudan University, Shanghai, People’s Republic of China
,
Yong Zhang1 Department of Oncology, Chinese PLA General Hospital, Beijing, People’s Republic of China, [email protected]
,
Xinru Mao10 Department of Medicine, Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China
,
Jianxing Xiang10 Department of Medicine, Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China
,
Ke Ma10 Department of Medicine, Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China
,
Bing Li11 Department of Bioinformatics, Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China
,
Tengfei Zhang10 Department of Medicine, Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China
&
Yi Hu1 Department of Oncology, Chinese PLA General Hospital, Beijing, People’s Republic of China, [email protected]Correspondence[email protected]
 show all
Pages 7323-7331 | Published online: 23 Oct 2018

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jun Ni & Li Zhang. (2021) Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations. OncoTargets and Therapy 14, pages 4087-4098.
Read now

Articles from other publishers (18)

Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou & Yi‐Long Wu. (2023) Genomic and immune characteristics of HER2 ‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy . Molecular Oncology.
Crossref
Bin Wang, Yang Song, Xin Yang & Chuan Chen. (2023) HER2 exon 20 insertion mutations and myelosuppression in lung adenocarcinoma patient: a case report and response to trastuzumab deruxtecan. Journal of Cardiothoracic Surgery 18:1.
Crossref
Sarah Waliany, Heather Wakelee, Kavitha Ramchandran, Millie Das, Jane Huang, Nathaniel Myall, Connie Li, Judy Pagtama, Alison Holmes Tisch & Joel W. Neal. (2022) Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer 23:6, pages 498-509.
Crossref
Birgit Wilding, Dirk Scharn, Dietrich Böse, Anke Baum, Valeria Santoro, Paolo Chetta, Renate Schnitzer, Dana A. Botesteanu, Christoph Reiser, Stefan Kornigg, Petr Knesl, Alexandra Hörmann, Anna Köferle, Maja Corcokovic, Simone Lieb, Guido Scholz, Jens Bruchhaus, Markus Spina, Josef Balla, Biljana Peric-Simov, Jasmin Zimmer, Sophie Mitzner, Thomas N. Fett, Alexandra Beran, Lyne Lamarre, Thomas Gerstberger, Daniel Gerlach, Markus Bauer, Andreas Bergner, Andreas Schlattl, Gerd Bader, Matthias Treu, Harald Engelhardt, Stephan Zahn, Julian E. Fuchs, Johannes Zuber, Peter Ettmayer, Mark Pearson, Mark Petronczki, Norbert Kraut, Darryl B. McConnell, Flavio Solca & Ralph A. Neumüller. (2022) Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nature Cancer 3:7, pages 821-836.
Crossref
Hui Li, Xiang Li, Shaowei Lan, Xuerong Zuo, Tianying Du, Ying Liu, Caixia Zhang, Jing Zhu & Ying Cheng. (2022) ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China . Tumori Journal, pages 030089162211014.
Crossref
Hong‐Xia Wu, Kai‐Quan Zhuo & Ke Wang. (2021) Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology 88:5, pages 2019-2034.
Crossref
Guangjian Yang, Haiyan Xu, Jiaqi Hu, Runze Liu, Peizeng Hu, Yaning Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Fei Xu, Xin Ai, Junling Li & Yan Wang. (2022) Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors. Frontiers in Pharmacology 13.
Crossref
Guangjian Yang, Yaning Yang, Runze Liu, Weihua Li, Haiyan Xu, Xuezhi Hao, Junling Li, Puyuan Xing, Shuyang Zhang, Xin Ai, Fei Xu & Yan Wang. (2022) First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study . Therapeutic Advances in Medical Oncology 14, pages 175883592210823.
Crossref
Zhengbo Song, Dongqing Lv, Shiqing Chen, Jianhui Huang, Liping Wang, Shuguang Xu, Huafei Chen, Guoqiang Wang & Quan Lin. (2021) Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study. Frontiers in Oncology 11.
Crossref
Gee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, Yuh-Min Chen, Jin-Yuan Shih, Shyam Aggarwal, Shuhang Wang, Sang-We Kim, Young-Chul Kim, Ibrahim Wahid, Rubi Li, Darren Wan-Teck Lim, Virote Sriuranpong, Raymond Tsz-Tong Chan, Robert M. Lorence, Philippe Carriere, Christina Raabe, Agnieszka Cseh & Keunchil Park. (2021) Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. International Journal of Clinical Oncology 26:5, pages 841-850.
Crossref
Jinchen Shao, Jiani C Yin, Hairong Bao, Ruiying Zhao, Yuchen Han, Lei Zhu, Xue Wu, Yang Shao & Jie Zhang. (2021) Morphological, immunohistochemical, and genetic analyses of bronchiolar adenoma and its putative variants. The Journal of Pathology: Clinical Research 7:3, pages 287-300.
Crossref
Jun Ni, Xiao‐yan Si & Li Zhang. (2021) Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report . Thoracic Cancer 12:8, pages 1244-1247.
Crossref
Sabine Zöchbauer-Müller, Bettina Kaserer, Helmut Prosch, Agnieszka Cseh, Flavio Solca, Markus Johann Bauer & Leonhard Müllauer. (2021) Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation. Frontiers in Oncology 10.
Crossref
Giulio Metro, Sara Baglivo, Riccardo Moretti, Guido Bellezza, Angelo Sidoni & Fausto Roila. (2020) Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review. Oncology and Therapy 8:2, pages 341-350.
Crossref
Jing Zhao & Yang Xia. (2020) Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review. JCO Precision Oncology:4, pages 411-425.
Crossref
Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang & Shucai Zhang. (2020) HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. Frontiers in Oncology 10.
Crossref
Bo Yuan, Jun Zhao, Chengzhi Zhou, Xiumei Wang, Bo Zhu, Minglei Zhuo, Xilin Dong, Jiemei Feng, Cuihua Yi, Yunpeng Yang, Hua Zhang, Wangyan Zhou, Zhengtang Chen, Sheng Yang, Xinghao Ai, Kehe Chen, Xuefan Cui, Difa Liu, Chunmei Shi, Wei Wu, Yanjun Zhang, Lianpeng Chang, Jin Li, Rongrong Chen & Shuanying Yang. (2020) Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib. Frontiers in Oncology 10.
Crossref
Fei Xu, Guangjian Yang, Haiyan Xu, Lu Yang, Weini Qiu & Yan Wang. (2020) Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China. Thoracic Cancer 11:3, pages 679-685.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.